336 related articles for article (PubMed ID: 24170764)
1. Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-30).
Landman GW; van Dijk PR; Drion I; van Hateren KJ; Struck J; Groenier KH; Gans RO; Bilo HJ; Bakker SJ; Kleefstra N
Diabetes Care; 2014; 37(3):839-45. PubMed ID: 24170764
[TBL] [Abstract][Full Text] [Related]
2. Inflammation biomarkers and mortality prediction in patients with type 2 diabetes (ZODIAC-27).
Landman GW; Kleefstra N; Groenier KH; Bakker SJ; Groeneveld GH; Bilo HJ; van Hateren KJ
Atherosclerosis; 2016 Jul; 250():46-51. PubMed ID: 27179179
[TBL] [Abstract][Full Text] [Related]
3. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31).
Riphagen IJ; Boertien WE; Alkhalaf A; Kleefstra N; Gansevoort RT; Groenier KH; van Hateren KJ; Struck J; Navis G; Bilo HJ; Bakker SJ
Diabetes Care; 2013 Oct; 36(10):3201-7. PubMed ID: 23757433
[TBL] [Abstract][Full Text] [Related]
4. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study.
Wild PS; Schnabel RB; Lubos E; Zeller T; Sinning CR; Keller T; Tzikas S; Lackner KJ; Peetz D; Rupprecht HJ; Bickel C; Morgenthaler NG; Papassotiriou J; Tiret L; Münzel T; Blankenberg S
Clin Chem; 2012 Jan; 58(1):226-36. PubMed ID: 22065157
[TBL] [Abstract][Full Text] [Related]
5. Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study.
Gar C; Thorand B; Herder C; Sujana C; Heier M; Meisinger C; Peters A; Koenig W; Rathmann W; Roden M; Stumvoll M; Maalmi H; Meitinger T; Then H; Seissler J; Then C
PLoS One; 2022; 17(1):e0262330. PubMed ID: 34990470
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress.
Sinning C; Ojeda F; Zeller T; Zengin E; Rupprecht HJ; Lackner KJ; Bickel C; Blankenberg S; Schnabel RB; Westermann D
Can J Cardiol; 2016 Dec; 32(12):1470-1477. PubMed ID: 27568502
[TBL] [Abstract][Full Text] [Related]
7. Serum Proenkephalin A Levels and Mortality After Long-Term Follow-Up in Patients with Type 2 Diabetes Mellitus (ZODIAC-32).
van Hateren KJ; Landman GW; Arnold JF; Joosten H; Groenier KH; Navis GJ; Sparwasser A; Bakker SJ; Bilo HJ; Kleefstra N
PLoS One; 2015; 10(7):e0133065. PubMed ID: 26218633
[TBL] [Abstract][Full Text] [Related]
8. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease.
Neumann JT; Tzikas S; Funke-Kaiser A; Wilde S; Appelbaum S; Keller T; Ojeda-Echevarria F; Zeller T; Zwiener I; Sinning CR; Jagodzinski A; Schnabel RB; Lackner KJ; Münzel T; Blankenberg S; Wild PS; Sydow K
Atherosclerosis; 2013 Jun; 228(2):451-9. PubMed ID: 23562132
[TBL] [Abstract][Full Text] [Related]
9. MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.
Falkentoft AC; Rørth R; Iversen K; Høfsten DE; Kelbæk H; Holmvang L; Frydland M; Schoos MM; Helqvist S; Axelsson A; Clemmensen P; Jørgensen E; Saunamäki K; Tilsted HH; Pedersen F; Torp-Pedersen C; Kofoed KF; Goetze JP; Engstrøm T; Køber L
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29776961
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
[TBL] [Abstract][Full Text] [Related]
11. Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort.
Saulnier PJ; Gand E; Velho G; Mohammedi K; Zaoui P; Fraty M; Halimi JM; Roussel R; Ragot S; Hadjadj S;
Diabetes Care; 2017 Mar; 40(3):367-374. PubMed ID: 27998909
[TBL] [Abstract][Full Text] [Related]
12. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P
Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731
[TBL] [Abstract][Full Text] [Related]
13. The influence of diabetes mellitus on midregional proadrenomedullin concentrations and prognostic value in heart failure outpatients.
Holmager P; Schou M; Egstrup M; Gustafsson I; Goetze JP; Gustafsson F; Klausen TW; Faber J; Kistorp C
J Card Fail; 2015 Mar; 21(3):250-7. PubMed ID: 25528198
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
15. Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29).
Drion I; Kleefstra N; Landman GW; Alkhalaf A; Struck J; Groenier KH; Bakker SJ; Bilo HJ
Diabetes Care; 2012 Nov; 35(11):2354-8. PubMed ID: 22837372
[TBL] [Abstract][Full Text] [Related]
16. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
[TBL] [Abstract][Full Text] [Related]
17. The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).
van Dijk PR; Landman GW; van Essen L; Struck J; Groenier KH; Bilo HJ; Bakker SJ; Kleefstra N
BMC Endocr Disord; 2015 Apr; 15():19. PubMed ID: 25880900
[TBL] [Abstract][Full Text] [Related]
18. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Funke-Kaiser A; Mann K; Colquhoun D; Zeller T; Hunt D; Simes J; Sullivan D; Sydow K; West M; White H; Blankenberg S; Tonkin AM;
Int J Cardiol; 2014 Mar; 172(2):411-8. PubMed ID: 24508492
[TBL] [Abstract][Full Text] [Related]
19. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
20. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
